Sipavibart, sold under the brand name Kavigale, is a medication used for the prevention of COVID-19 in people who are immunocompromised.Sipavibart is a recombinant human IgG1 monoclonal antibody that provides passive immunization against SARS-CoV-2 by binding its spike protein receptor binding domain.

Sipavibart was authorized for medical use in the European Union in January 2025.

Medical uses

Sipavibart is indicated for the pre-exposure prophylaxis of COVID-19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb) and who are immunocompromised due to a medical condition or receipt of immunosuppressive treatments

‍